Breaking News Instant updates and real-time market news.

SRRK

Scholar Rock

$17.97

-0.065 (-0.36%)

16:10
06/03/19
06/03
16:10
06/03/19
16:10

Scholar Rock announces final top-line results from Phase 1 SRK-015 trial

Scholar Rock announced final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific inhibitor of myostatin activation, in healthy adult volunteers. Consistent with previously announced interim findings, the final results showed target engagement and no apparent safety signals were observed across all tested doses. Detailed results from the Phase 1 trial will be presented at the Cure SMA annual conference. In the single-ascending dose, or SAD, portion of the trial, adverse events, or AEs, were observed in 30% of SRK-015-treated subjects and 50 % of placebo-treated subjects. In the multiple-ascending dose, or MAD, portion of the trial, AEs were observed in 35% of SRK-015-treated subjects and 67% of placebo-treated subjects. There were no discontinuations due to a treatment-related AE, no hypersensitivity reactions and no deaths. A single serious AE of gallstone-induced pancreatitis was observed in an SRK-015-treated subject and was assessed by the trial investigator as unrelated to treatment. Immunogenicity as evaluated by anti-drug antibody testing was negative for all SRK-015 treated subjects in the trial. Target engagement was shown in the Phase 1 trial through increases from baseline in levels of latent myostatin. The levels of target engagement attained a plateau after a single dose of SRK-015 at 3 mg/kg or greater, suggesting target saturation. This plateau was sustained up to Day 84 after a single dose at 20 mg/kg. This durability of effect was further shown in the MAD portion of the trial, during which the plateau was sustained up to at least day 140 after three doses given once every two weeks at 20 mg/kg or 30 mg/kg. In contrast, no meaningful change was observed in the latent myostatin biomarker concentrations in subjects who received placebo. PD was evaluated through a proprietary, exploratory biomarker assay developed by Scholar Rock that measures serum concentrations of latent myostatin. This assay was used previously to measure target engagement in preclinical studies in healthy animals and a mouse model of SMA. Pharmacokinetic, or PK, data. Drug exposure to SRK-015 was dose-proportional and SRK-015's serum half-life was 23-33 days across dose cohorts. In these respects, SRK-015 displayed a PK profile consistent with what is commonly observed for monoclonal antibodies.

  • 04

    Jun

  • 05

    Jun

SRRK Scholar Rock
$17.97

-0.065 (-0.36%)

06/18/18
WEDB
06/18/18
INITIATION
Target $25
WEDB
Outperform
Scholar Rock initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Scholar Rock with an Outperform rating and $25 price target saying it is taking a unique approach to inhibiting TGF beta, a key class of interest for drug developers but one considered too difficult to drug with specificity, by locking the proteins in their latent state. This strategy, and supportive preclinical data, give him confidence that the company's programs could be the first to safely shut down TGF beta signaling in a targeted manner, with application in several serious disorders.
06/18/18
BMOC
06/18/18
INITIATION
Target $31
BMOC
Outperform
Scholar Rock initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Scholar Rock with an Outperform rating and a price target of $31, citing his expectations of its proprietary research platform answering the challenges of modulating transforming growth factor beta signaling pathways. The analyst adds that the company's SRK-015 program has "properly aligned the drug's specific benefit to an ideal disease setting" and expects the Phase 1 data in Q4 to confirm its safety and PK/PD profile, with eventual proof-of-concept data coming in the second half of 2019.
06/18/18
JEFF
06/18/18
INITIATION
Target $26
JEFF
Buy
Scholar Rock initiated with a Buy at Jefferies
Jefferies analyst Michael Yee started Scholar Rock with a Buy rating and $26 price target. Similar to other orphan drug stories, early data could offer 50%-plus upside into 2019 if they show early benefit in spinal muscular atrophy patients, Yee tells investors in a research note.
06/18/18
COWN
06/18/18
INITIATION
Target $18
COWN
Outperform
Scholar Rock initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Scholar Rock with an Outperform rating as she believes its lead product, SRK-015, which is a myostatin activation inhibitor in development for SMA type 2 and 3, has significant clinical promise with peak potential U.S. sales of $1.6B. Baral has an $18 price target on Scholar Rock shares.

TODAY'S FREE FLY STORIES

SNAP

Snap

$14.08

-0.5 (-3.43%)

14:49
10/22/19
10/22
14:49
10/22/19
14:49
Options
Snap Inc. options imply 26.3% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 21

    Nov

GILD

Gilead

$66.32

1.11 (1.70%)

14:45
10/22/19
10/22
14:45
10/22/19
14:45
Options
Gilead call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 07

    Dec

SPY

SPDR S&P 500 ETF Trust

$300.58

0.53 (0.18%)

, SPX

S&P 500

$0.00

(0.00%)

14:41
10/22/19
10/22
14:41
10/22/19
14:41
General news
U.K. Parliament rejects timetable bill for exit from EU »

U.K. lawmakers rejected a…

SPY

SPDR S&P 500 ETF Trust

$300.58

0.53 (0.18%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$340.23

9.11 (2.75%)

14:34
10/22/19
10/22
14:34
10/22/19
14:34
On The Fly
Fly Intel: What to watch in Boeing's earnings report »

Boeing (BA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FB

Facebook

$183.45

-6.37 (-3.36%)

, GOOG

Alphabet

$1,246.51

0.28 (0.02%)

14:25
10/22/19
10/22
14:25
10/22/19
14:25
Periodicals
U.S antitrust chief says breakup of 'Big Tech' is 'on the table,' WSJ reports »

Makan Delrahim, the U.S.…

FB

Facebook

$183.45

-6.37 (-3.36%)

GOOG

Alphabet

$1,246.51

0.28 (0.02%)

AMZN

Amazon.com

$1,769.36

-15.37 (-0.86%)

AAPL

Apple

$242.10

1.61 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 21

    Nov

GME

GameStop

$6.30

0.37 (6.24%)

14:25
10/22/19
10/22
14:25
10/22/19
14:25
Options
GameStop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SPY

SPDR S&P 500 ETF Trust

$300.50

0.45 (0.15%)

, SPX

S&P 500

$0.00

(0.00%)

14:17
10/22/19
10/22
14:17
10/22/19
14:17
General news
Brexit withdrawal agreement bill passes by 329-299 vote, Bloomberg reports »

The U.K. Parliament is…

SPY

SPDR S&P 500 ETF Trust

$300.50

0.45 (0.15%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/22/19
10/22
14:17
10/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/22/19
10/22
14:16
10/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
10/22/19
10/22
14:10
10/22/19
14:10
Conference/Events
Senate Commerce, Science & Transportation Committee to hold a hearing »

The Subcommittee on…

UTX

United Technologies

$141.32

3.08 (2.23%)

, BA

Boeing

$339.38

8.26 (2.49%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09
Periodicals
United Tech sees no extra cut in Boeing 737 MAX production in 2019, Reuters says »

United Technologies (UTX)…

UTX

United Technologies

$141.32

3.08 (2.23%)

BA

Boeing

$339.38

8.26 (2.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

LLY

Eli Lilly

$109.84

1.9 (1.76%)

14:09
10/22/19
10/22
14:09
10/22/19
14:09
Earnings
Fly Intel: What to watch in Eli Lilly earnings report »

Eli Lilly (LLY) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

FCX

Freeport McMoRan

$9.95

0.13 (1.32%)

14:05
10/22/19
10/22
14:05
10/22/19
14:05
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WBS

Webster Financial

$44.80

-2.51 (-5.31%)

14:01
10/22/19
10/22
14:01
10/22/19
14:01
Downgrade
Webster Financial rating change  »

Compass Point cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

WBS

Webster Financial

$44.69

-2.62 (-5.54%)

13:58
10/22/19
10/22
13:58
10/22/19
13:58
Downgrade
Webster Financial rating change  »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

13:55
10/22/19
10/22
13:55
10/22/19
13:55
Conference/Events
House Financial Services Committee to hold a hearing »

The Subcommittee on…

SYMC

Symantec

$23.19

0.11 (0.48%)

13:55
10/22/19
10/22
13:55
10/22/19
13:55
Conference/Events
House Committee on Homeland Security to hold a hearing »

The Cybersecurity,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

LYFT

Lyft

$44.73

3.87 (9.47%)

, UBER

Uber

$33.79

2.375 (7.56%)

13:47
10/22/19
10/22
13:47
10/22/19
13:47
Recommendations
Lyft, Uber analyst commentary  »

Lyft profit call…

LYFT

Lyft

$44.73

3.87 (9.47%)

UBER

Uber

$33.79

2.375 (7.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

FEYE

FireEye

$15.67

0.255 (1.65%)

13:45
10/22/19
10/22
13:45
10/22/19
13:45
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 09

    Dec

  • 12

    Dec

13:45
10/22/19
10/22
13:45
10/22/19
13:45
General news
Treasury Action: the 2-year yield dropped on the good auction results »

Treasury Action: the…

MCD

McDonald's

$201.55

-8.295 (-3.95%)

13:45
10/22/19
10/22
13:45
10/22/19
13:45
Recommendations
McDonald's analyst commentary  »

McDonald's price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PRGS

Progress Software

$39.56

-0.06 (-0.15%)

13:44
10/22/19
10/22
13:44
10/22/19
13:44
Initiation
Progress Software initiated  »

Progress Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BIIB

Biogen

$291.60

68.03 (30.43%)

13:39
10/22/19
10/22
13:39
10/22/19
13:39
Recommendations
Biogen analyst commentary  »

Biogen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JBHT

J.B. Hunt

$116.80

1.42 (1.23%)

, KNX

Knight-Swift

$37.00

0.17 (0.46%)

13:38
10/22/19
10/22
13:38
10/22/19
13:38
Hot Stocks
ATA says truck tonnage index rose 0.2% in September »

American Trucking…

JBHT

J.B. Hunt

$116.80

1.42 (1.23%)

KNX

Knight-Swift

$37.00

0.17 (0.46%)

ODFL

Old Dominion

$179.81

-0.14 (-0.08%)

SWFT

Swift Transportation

$0.00

(0.00%)

WERN

Werner

$37.39

0.47 (1.27%)

ARCB

ArcBest

$29.91

-0.62 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 01

    Nov

  • 13

    Nov

BA

Boeing

$338.95

7.83 (2.36%)

, TMO

Thermo Fisher

$283.75

0.3 (0.11%)

13:36
10/22/19
10/22
13:36
10/22/19
13:36
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BA

Boeing

$338.95

7.83 (2.36%)

TMO

Thermo Fisher

$283.75

0.3 (0.11%)

LLY

Eli Lilly

$109.81

1.87 (1.73%)

CAT

Caterpillar

$132.73

0.51 (0.39%)

ANTM

Anthem

$263.46

10.3 (4.07%)

BX

Blackstone

$49.33

0.225 (0.46%)

BSX

Boston Scientific

$38.79

0.13 (0.34%)

GD

General Dynamics

$179.02

3.59 (2.05%)

NSC

Norfolk Southern

$187.37

1.2 (0.64%)

HLT

Hilton

$92.41

0.03 (0.03%)

FCX

Freeport McMoRan

$9.96

0.14 (1.43%)

IVZ

Invesco

$16.13

-0.015 (-0.09%)

OC

Owens Corning

$63.55

0.085 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 02

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.